August 02, 2021
The Patent Trial and Appeal Board has found that claims in two polymer patents that cover a hemophilia treatment developed by Nektar Therapeutics are obvious in light of a collection of prior art.
March 09, 2020
In a series of three redacted institution decisions from February that were unsealed Friday, the Patent Trial and Appeal Board rejected Nektar Therapeutics' argument that NOF Corporation's petitions should be denied because they failed to name Bayer as a real party in interest.